Coverage across a range of pathogens commonly encountered in CAP, Including Streptococcus pneumoniae and MSSA1-4
In Vitro Susceptibility: MIC Break Points Established by the EUCAST for ZINFORO®1,4,*
Header | ||
---|---|---|
Header | Header | Header |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
In vitro activity does not always correlate with clinical efficacy.
*Efficacy has been demonstrated in CAP clinical studies against the following pathogens that were susceptible to ceftaroline in vitro: S. pneumoniae, S. aureus (methicillin-susceptible strains only), E. coli, H. influenzae, H. parainfluenzae and K. pneumoniae.
Efficacy has been demonstrated in clinical studies of cSSTI against pathogens that were susceptible to ceftaroline in vitro.1
†Refers to the dosing of adults with ceftaroline q12h using 1-hour infusions.1
‡Refers to the dosing of adults with ceftaroline q8h using 2-hour infusions to treat cSSTI. S. aureus with ceftaroline MICs ≥4 mg/mL are rare. PK/PD analyses suggest that dosing of adults with ceftaroline q8h using 2-hour infusions may treat cSSTI due to S. aureus for which ceftaroline MIC is 4 mg/mL.1
§Available clinical data cannot substantiate efficacy against PNSP. In vitro data indicate that the following atypical species are not susceptible to ceftaroline: Chlamydophila spp., Legionella spp., Mycoplasma spp., Proteus spp. and P. aeruginosa.1
¶Inferred by susceptibility to benzylpenicillin.4
CAP, community-acquired pneumonia; CE, clinically evaluable; CI, confidence interval; cSSTI, complicated skin and soft tissue infection; EOT, end of treatment; FOCUS, ceFtarOline Community-acquired pneUmonia trial vS ceftriaxone in hospitalized patients; ITT, intent-to-treat; IV, intravenous; LFU, late follow-up; ME, microbiologically evaluable; MITT, modified intent-to-treat; MITTE, modified intent-to-treat efficacy; mMITT, microbiologically modified intent-to-treat; PORT, Pneumonia Patient Outcomes Research Team; q8h, every 8 hours; q12h, every 12 hours.
References:
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.